Cardiovascular Drugs Market Uses NOACs For The Convenience Of Patients
Cardiovascular Drugs Global Market Report 2022 – Market Size, Trends, And Global Forecast 2022-2026
The Business Research Company’s Cardiovascular Drugs Global Market Report 2022 – Market Size, Trends, And Global Forecast 2022-2026
LONDON, GREATER LONDON, UK, January 27, 2022 /EINPresswire.com/ -- NOACs are gaining wider acceptance and are replacing traditionally used anti-coagulants such as Warfarin and Heparin. Anti-coagulants have long been used in prevention of thrombus formation in patients suffering with cardiovascular diseases. The global cardiovascular drugs market outlook changed with the use of NOACs making it easier for patients to continue therapy post discharge, as opposed to injections of Heparin and Warfarin which need medical assistance for administration. Some of the NOACs include Pradaxa (dabigatran etexilate) from Boehringer Ingelheim, Xarelto (rivaroxaban) from Janssen, and Eliquis (apixaban) from Bristol-Myers Squibb.
North America was the largest region in the cardiovascular drugs market in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the cardiovascular drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Read More On The Global Cardiovascular Drugs Market Report:
https://www.thebusinessresearchcompany.com/report/cardiovascular-drug-global-market-report
The global cardiovascular drugs market size is expected to grow from $146.51 billion in 2021 to $153.60 billion in 2022 at a compound annual growth rate (CAGR) of 4.8%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The global cardiovascular drugs market share is expected to reach $205.71 billion in 2026 at a CAGR of 7.6%.
The rise in sedentary jobs, busy lifestyles and changing consumer preferences are affecting the disease profile of the world population, especially non-communicable diseases such as cancer, diabetes and cardiovascular diseases. Long working hours, less physical activity, and unhealthy eating and drinking habits are major causes of cardiovascular diseases including hypertension. According to the World Health Organization, chronic disease prevalence is rose by 57% globally, in the year 2020. These factors are expected to increase the patient pool globally, thereby driving the cardiovascular drugs industry growth during the forecast period.
Major players covered in the global cardiovascular drugs industry are Medtronic Inc., Boston Scientific Corporation, Abbott Laboratories, Edwards Lifesciences, Cardinal Health, Inc., Johnson & Johnson, Terumo Corporation, Getinge Group, Teleflex Inc. and Becton Dickinson.
TBRC’s global cardiovascular drugs market report is segmented by type into anti-hypertensive drugs, hypolipidemics, anti thrombotics, other drugs for cardiovascular diseases (congestive heart failure, anti-arrhythmic and anti-anginal drugs), by distribution channel into hospital pharmacies, retail pharmacies/ drug stores, others, by route of administration into oral, parenteral, others, by drug classification into branded drugs, generic drugs, by mode of purchase into prescription-based drugs, over-the-counter drugs.
Cardiovascular Drugs Global Market Report 2022 – By Type (Anti-Hypertensive Drugs, Hypolipidemics, Anti Thrombotics, Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrhythmic And Anti-Anginal Drugs)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others), By Route Of Administration (Oral, Parenteral, Others), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Prescription-Based Drugs, Over-The-Counter Drugs) – Market Size, Trends, And Global Forecast 2022-2026 is one of a series of new reports from The Business Research Company that provides a cardiovascular drugs market overview, forecast cardiovascular drugs market size and growth for the whole market, cardiovascular drugs market segments, geographies, cardiovascular drugs market trends, cardiovascular drugs market drivers, restraints, leading competitors’ revenues, profiles, and market shares.
Request For A Sample Of The Global Cardiovascular Drugs Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2134&type=smp
Not what you were looking for? Here is a list of similar reports by The Business Research Company:
Anti-Hypertensive Drugs Global Market Report 2021 - By Therapeutics (Diuretics, Angiotensin Receptor Blockers (ARBs), Angiotensin Converting Enzyme (ACE) Inhibitors, Beta Blockers, Alpha Blockers, Calcium Channel Blockers, Renin Inhibitors, Vasodilators), By Disease Source (Primary Hypertension, Secondary Hypertension), By End Users (Hospitals, Clinics, Homecare), COVID-19 Impact And Recovery
https://www.thebusinessresearchcompany.com/report/anti-hypertensive-drugs-global-market-report
Hypolipidemics Global Market Report 2021 - By Product Type (Cholic Acid Regulator, HMG-CoA Reductase Inhibitors, Adenylate Cyclase Inhibitors, Nicotinic Acid Drugs), By Application (Hospital, Clinics, Pharmacy, Cardiovasology), COVID-19 Impact and Recovery
https://www.thebusinessresearchcompany.com/report/hypolipidemics-global-market-report
Anti-Asthmatic And COPD Drugs Market 2021 - By Drug Class (Bronchodilators, Monoclonal Antibodies, Anti-Inflammatory Drugs, Combination Drugs), By End User (Asthma Patients, COPD Patients), By Distribution Channel (General Pharmacies, Hospital Pharmacies, Online Retailers), By Therapy (Preventive, Curative), By Route Of Administration (Oral, Inhaled, Intravenous, Subcutaneous), By Age Group (Below 5, 5-14, 15-60, Above 60), By Prescription (Prescription, Over The Counter (OTC)), By Drug Type (Branded, Generic) And By Region, Opportunities And Strategies – Global Forecast To 2030
https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-market
About The Business Research Company?
The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.
Read more about us at https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx
Call us now for personal assistance with your purchase:
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Check out our:
LinkedIn: https://bit.ly/3b7850r
Twitter: https://bit.ly/3b1rmjS
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: http://blog.tbrc.info/
Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info
Visit us on social media:
Facebook
Twitter
LinkedIn
EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.
